在高血压ICH中TIE2表达及其与AKB-9778的治疗调制:对大脑血管健康的影响
Jingkun Wu1, Hongbin Wang1, Naizhu Wang1
1Department of Neurosurgery, Affiliated Hospital of Hebei Engineering University, Handan 056002, PR China.
Experimental neurology
|January 9, 2024
概括
这项研究表明,减少TIE2 (具有免疫球蛋白类和EGF类域2的铁酸酶) 表达有助于高血压脑内出血 (ICH). 用AKB-9778激活TIE2显示出对ICH的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 血管生物学 血管生物学
- 分子医学是分子医学.
背景情况:
- 高血压脑内出血 (ICH) 是一种严重的神经疾病,分子机制不明.
- 确定ICH病变发生的关键分子参与者对于开发有效治疗方法至关重要.
研究的目的:
- 研究氨酸激酶与免疫球蛋白类和EGF类域2 (TIE2) 在高血压ICH的发展中的作用.
- 在ICH模型中探索针对TIE2的治疗潜力.
主要方法:
- 使用高通量转录组测序和网络药理学分析.
- 使用人类大脑微血管内皮细胞 (HBMEC) 进行了体外研究,并在高血压ICH小鼠模型中进行了体内实验.
- 小分子AKB-9778被用来准和激活TIE2.
主要成果:
- 在高血压ICH小鼠的大脑血管中,TIE2表达显著下调.
- TIE2调制通过Rap1/MEK/ERK通路影响了内皮细胞的增殖,迁移和血管生成.
- AKB-9778激活了TIE2,并且在与抗高血压药物结合时,在ICH小鼠模型中减少了出血.
结论:
- TIE2在高血压ICH的发病过程中起着至关重要的作用.
- 用AKB-9778针对TIE2是一个有希望的治疗策略,可以缓解ICH.
- 联合治疗AKB-9778和抗高血压药物可能提供显著的临床益处.
更多相关视频
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
8.9K
12:19An In Vivo Assessment of Blood-Brain Barrier Disruption in a Rat Model of Ischemic Stroke
Published on: March 11, 2018
11.4K
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432